ChromaDex signs agreement for commercial development of pterostilbene from University of Mississippi and USDA

A natural products chemistry company has licensed the rights for a promising botanical compound from the University of Mississippi and the Agricultural Research Service, which is the principal intramural scientific research agency of the U.S. Department of Agriculture.

ChromaDex Corp. has signed an agreement for the commercial development of pterostilbene (tero-STILL-bean), a compound found in blueberries, grapes and other small fruits, as well as the bark of some trees. In laboratory tests, it shows promise for improving cardiovascular health, glucose levels and cognitive function.

"Pterostilbene has the potential to be one of the most significant new ingredients the dietary supplement field has seen in a long time," said Frank L. Jaksch Jr., co-founder and CEO of ChromaDex. "Based on the technology we licensed from the University of Mississippi and the USDA, ChromaDex will be announcing the commercial application of this ingredient, marketed as pTeroPure pterostilbene, in the coming weeks."

Pterostilbene is chemically related to resveratrol, a compound that is plentiful in the skins of red grapes. Resveratrol is thought to be at least partly responsible for the health benefits attributed to drinking red wine, which include cardiovascular health and cancer prevention.

Research chemist Agnes Rimando first encountered pterostilbene when she was a graduate student at the University of Chicago. Rimando works with the USDA Agricultural Research Service, Natural Products Utilization Research Unit, housed in the UM National Center for Natural Products Research. When studies in the 1990s suggested that resveratrol provided substantial health benefits, Rimando began experimenting with pterostilbene in hopes of finding similar activity.

In 2003, Rimando asked Dennis Feller, former UM professor and chair of pharmacology, and Wallace Yokoyama at USDA-ARS Western Regional Research Center in Albany, Calif., to collaborate on studies of the compound, targeting a particular protein in cells that is involved in fatty acid metabolism and transport. Results of their work were presented at the American Chemical Society meeting in 2004 and attracted widespread attention, including coverage on national and international TV and radio stations, and mentions in Time, Parade and other consumer magazines.

The development of pterostilbene as a potential dietary supplement demonstrates the value of collaborations between the School of Pharmacy, NCNPR and USDA-ARS, said Barbara G. Wells, dean of the UM pharmacy school.

"These types of projects allow us to share expertise and help solve problems related to the health and well-being of people everywhere," Wells said. "We actively seek partnerships with other academic institutions and state and federal agencies, and we are pleased that this particular partnership has yielded such encouraging results."

The licensing agreement with ChromaDex is a prime example of how academic research can promote economic development, said Walt Chambliss, UM director of technology management.

"ChromaDex is just the kind of company we want to work with," Chambliss said. "They know the value of our research, and that's the key ingredient in a partnership like this.

"UM and USDA-ARS researchers working at Ole Miss share a common desire to translate research into commercial products. We couldn't be happier about our agreement with ChromaDex. It's just further testament to the ability of our researchers to do work that attracts commercial interest."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SRF awards $230,000 grant to advance research on SYNGAP1-Related Disorders